Polares Medical Closes a $40M Financing to Complete Pilot Clinical Studies
Longitude Capital and other top-class VCs from around the world invest in Polares Medical. The Series B financing allows the company to advance its clinical studies. Polares Medical was spun off in 2017 from Symetis SA prior to the acquisition of Symetis by Boston Scientific. Polares Medical SA, a clinical stage medical technology company based in Lausanne announced today the closing of a $40 million financing led by Longitude Capital (Menlo Park) with the participation of Decheng Capital(Menlo Park / Shanghai), Endeavour Vision (Geneva), IDO Investments(Muscat), Earlybird Venture Capital (Berlin), and Wellington Partners(Munich). The company is focused on the development of a unique mitral valve hemi-replacement system to treat…
‘Prodigy’ founder taking Utah’s Teal Drones to unexplored heights
MURRAY — Smaller. Faster. Smarter. Common goals in the world of tech startups, but Teal Drones founder and CEO George Matus — having nailed these three attributes very early on with drones he and his team developed — is on a quest for something more elusive and, perhaps, more consequential. “Once consumer drones started becoming widely used and really popular, I started realizing that all they are is just a flying camera that can take photos and videos,” Matus said. “And, I’ve always had these grand visions of what drones could do … and the role for good that they…
Fractyl’s Revita DMR Same-Day Therapeutic Procedure Could End Daily Insulin Injections for Type 2 Diabetes Patients
Interim clinical data to be presented at ADA 2019 show that approximately 85 percent of patients are insulin-free at six months after Revita DMR outpatient therapy LEXINGTON, Mass., June 8, 2019 — Fractyl Laboratories Inc. (Fractyl), today announced the presentation of interim data from the investigator-initiated INSPIRE clinical trial in collaboration with Fractyl showing Revita™ DMR, a same-day therapeutic procedure, can help eliminate the need for daily insulin injections for type 2 diabetes (T2D) patients. This data will be presented at the American Diabetes Association’s 79th Scientific Sessions in San Francisco on Sunday, June 9 from 12 pm to 1 pm….
Allurion expands in Natick, raises $60M
Allurion, a Natick company making a gastric weight-loss balloon that doesn’t require an operation, doesn’t yet have regulatory approval to sell in the United States. But Allurion does sell the Elipse Balloon in Europe and the Middle East, and with 15,000 sold in its three years in those markets, Allurion has made a major expansion with high hopes. “It’ll allow us to touch the lives of millions, if not billions, of people around the world,” Shantanu Gaur, Allurion’s CEO and co-founder, said Friday, officially opening the company’s new 10,000-square-foot office and lab on Erie Drive in Natick. The new space…